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A plea to provide best evidence in trials
under sample-size restrictions: the example
of pioglitazone to resolve leukoplakia and
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Abstract
In planning a clinical trial for demonstrating the efficacy of pioglitazone to resolve leukoplakia and erythroplakia in
Fanconi anemia patients we had to discuss the need for a randomized controlled trial particularly under sample-size
restrictions as very promising results were available from a single-arm clinical trial. Unfortunately, at a later stage, we had
to suffer from the fact that single-arm clinical trials may sometimes mislead. When revisiting our planning at a later stage
of a grant application, results of a randomized controlled trial had become available which were less impressive, but may
still be of clinical interest. However, these results were perceived as disappointing in the light of previously raised hopes
based on the results of the single-arm trial. We highlight some major problems when research is based on single-arm
trials compared to randomized controlled trials. After debunking common arguments for the conduct of single-arm trials
in rare disease we conclude that particularly in rare disease research should be based on randomized building blocks
simply because more robust evidence is generated. The plea for single-arm trials should be substituted by a plea for
cooperation of all stakeholders to provide best evidence for decision making under sample-size restrictions.
Keywords: Randomization, Single-arm trial, RCT, Rare disease, Historical control, Fanconi anemia, Study planning,
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Background
Randomized controlled trials (RCTs) with one control
arm and at least one new treatment arm are the gold
standard to inform about treatment efficacy, safety, and
benefit-/risk-ratio. The re-emerging big data discussion
reflects the hope that (unsystematic) large data collec-
tions can replace careful research into the efficacy and
safety of treatments in certain (sub-)indications. In this
context the use of historical data from registries or pre-
vious RCTS to replace a concurrent randomized control
arm [1] is discussed. This approach essentially leads to
the conduct of single-arm trials for which new method-
ology has been proposed to incorporate the historical in-
formation [2]. Researchers in the field of and patients
suffering from rare diseases seem to be big advocates of
such trials. This can be seen in a recent comparison of
interventional clinical trials in rare and non-rare dis-
eases, where it has been shown that the majority of trials
in rare diseases are single-arm trials (63%) compared to
29% in non-rare diseases [3]. Strictly speaking it is only
possible to evaluate the outcome of a single-arm trial, if
the natural history (development/course) of disease is
fully understood and constant over time so that it is fully
clear that seemingly different outcomes beyond known
prognostic factors between the experimental treatment
and the historical control can only be caused by differ-
ences between treatments [4]. In other words, every time
a single-arm trial is conducted, the researchers assume
that the outcome in the control group (placebo or stand-
ard of care) is entirely known and not subjected to
patient selection, or temporal effects. In consequence,
relying on the counterfactual (the expected/hypothetical
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response in a control group) derived from registries or
historical controls raises two issues:
1. The estimated difference between treatment and
counterfactual might be biased and the potential
drawbacks of using historical controls or registries
have been discussed in many places [5, 6] and also
apply here.
2. When the counterfactual is assumed to be known
well enough and a single-arm trial is conducted,
the underlying assumption of consistency of effects
seen in the past and in the non-investigated control
group is obviously not testable with the trial data.
In case the control group is lacking, all hope is on
circumstantial evidence to detect possible violations
of the assumption.
It is worth noting that these issues are even more pro-
nounced in rare diseases, where often less information
from registries or prior studies is available. Even if informa-
tion is available, it would obviously have lower precision
than in frequent disease, and therefore, the counterfactual
is squishier. As stated above, paradoxically, in rare diseases
the proportion of single-arm trials is more than doubled
compared to non-rare diseases [3].
In this paper, we are revisiting the planning of a ran-
domized trial in a rare disease. In planning a clinical trial
in Fanconi anemia (FA) we had to first discuss the need
for randomisation and, unfortunately, at a later stage, suf-
fer from the fact that single-arm clinical trials may some-
times mislead. We will first introduce the rare disease and
the clinical evidence that was available to us in our plan-
ning meetings, before trying to explain all the hurdles that
we faced while planning and a possible solution.
A real-life example
FA is a rare inherited chromosomal instability syndrome
characterized by congenital abnormalities, bone marrow
failure and a predisposition to cancers including leukemia
and solid tumors. Notably, the risk of head and neck squa-
mous cell carcinoma (SCC) in FA is 500-fold higher in
comparison with the general population [7]. FA-associated
head and neck SCC is most commonly located in the oral
cavity and surgery is the mainstay of therapy. Unfortu-
nately, patients frequently present with late-stage disease
and/or multiple lesions diminishing the utility of surgery.
Still more, the role of adjuvant chemo- or radiotherapy for
head and neck SCC in FA is limited because patients do
not tolerate these therapies due to their underlying
chromosomal instability. Not surprisingly, many FA pa-
tients relapse after therapy and eventually succumb to
their cancer in less than 2 years after diagnosis [7]. Thus,
systemic therapy at a premalignant stage of oral cancer
appears to be a good option to prevent the development
of an overt malignant tumor.
Patients with and without FA have premalignant
oral lesions called leukoplakia, erythroplakia or leuko-
erythroplakia and some of the lesions progress to oral
SCC. Cellular and animal preclinical data suggested that
pioglitazone, an oral hypoglycemic medication used in
type 2 diabetes mellitus, may be beneficial for resolving
these at-risk lesions. In an uncontrolled, open-label,
single-arm clinical trial involving 21 non-FA patients ad-
ministered 45mg of pioglitazone daily for 12 weeks, 15/21
(68%) of the patients showed a partial or complete involu-
tion of their oral premalignant lesions [8]. The estimated
partial or complete spontaneous remission rate of oral leu-
koplakia, erythroplakia or leuko-erythroplakia in non-FA
patients was less than 5% in the personal experience of
our local oral surgeon. Given this information, the as-
sumed treatment effect (the difference between observed
treatment response and assumed counterfactual) was 63%.
With this prior knowledge, arguing for the conduct of
an RCT in FA-patients is difficult. Arguments against
randomization were the unwillingness of the patients to
accept an inferior treatment when informed about the
promising outcome of the single-arm clinical trial and
the observed dramatic effect unlikely to be a pure
chance finding. Despite little data on the natural course
of disease, both, in FA- and non-FA patients, clinical
equipoise was lost.
Subsequently, the results of a randomized placebo-
controlled trial (N = 52) for the efficacy of 15 mg pioglit-
azone thrice daily for 24 weeks in non-FA patients
became available. They showed a partial or complete re-
sponse rate of 46% (12/26) in the pioglitazone group and
32% (8/25) response rate in the placebo group [9]. This
RCT was terminated due to slow accrual after half of the
planned sample size of 100 participants was recruited.
Although in this randomized trial the treatment effect
was estimated as 14%, compared with the impressive re-
sults from the single-arm clinical trial, the results were
felt to be disappointing.
This perceived setback unfortunately prevented further
discussion, e.g. whether a treatment effect of roughly
14% introduced by a rather non-toxic or debilitating
treatment (as compared to surgery, or chemotherapy as
the standard options for premalignant lesions or oral
cancer) would indeed be an improvement large enough
to continue research. In consequence, long-term effects
not only on resolving leukoplakia and erythroplakia but
also on oral cancer will not be evaluated.
A case for RCTs in rare diseases
The striking differences in results between the single-
arm and the randomized controlled trial in this instance
underscore the notion that the assumption of knowing
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the counterfactual may be easily violated. By conducting
a single-arm trial in an early development phase re-
searchers implicitly or explicitly ignore this issue. There-
after, planning an RCT based on the outcome in a
single-arm trial most likely results in an overestimated
treatment effect due to the missing adjustment for the
outcome with the current standard or placebo, resulting
in a trial underpowered to detect the true treatment ef-
fect. Even worse, the final decision could be based on
perceived large treatment effects and further research to
replicate the findings may not even be conducted.
Selection bias is one of the main sources responsible
for overestimation (or seldom underestimation) of effect.
If treatment is not randomly allocated between groups,
there is no way of knowing which of the observed effect
is due to treatment efficacy and which is due to popula-
tion characteristics. A response rate of 68% for pioglita-
zone in the single-arm trial compared to a response rate
for pioglitazone of 46% in the RCT might indicate that
different populations have been studied. Most often pa-
tients with a more promising prognosis will be recruited
for a single-arm trial. Whenever those prognostic factors
that would describe the better patient prognosis are not
recorded, not analyzed, or even not known, the single-
arm trial is not able to identify these factors.
Controlled observational studies or, generally, study
designs, which include some sort of control data without
randomizing treatment allocation, most likely suffer
from the same issue, because different populations might
have been selected for the treatment and control group:
patients with specific predispositions might (not) be allo-
cated to the treatment group because a higher benefit
(risk) is assumed [10] In contrast, randomization will
“on average” balance all known and unknown con-
founders between treatment groups and the estimated
treatment effect is adjusted for confounders by default.
A fundamental epistemological principle is proof of effi-
cacy in a formal regimented setting; yet, current literature
appears to rationalize the inability to complete RCTs. Par-
ticularly, in the field of rare diseases, there seems to be an
increasing unwillingness to go for best evidentiary stan-
dards (e.g. [11–13]). The pioglitazone-example clearly
demonstrates all the downsides of this approach.
It seems that not much has changed since 1975 in the
discussion about clinical trial design [14] and unfortu-
nately, the issue remains whether randomization is ne-
cessary, or can be avoided altogether (e.g. [15]). Often in
rare diseases, there are arguments that limited sample
size prohibits randomization or that outcomes will be
dramatic and a single-arm trial will suffice to unequivo-
cally substantiate the efficacy of a treatment. However,
Prasad & Oseran concluded that for rare cancers, the
issue of randomization (or lack of randomization) in
clinical trials is more likely related to our expectations in
the research community, rather than different tumor in-
cidences [16]. If the above arguments hold true, there
should be a proportionate correlation between disease
incidence and the number of RCTs conducted in the dis-
ease. In rare cancers, the percentage of RCTs did not
change even though there is a 6-fold difference in inci-
dences of these cancers [17]. Similarly, the Institute for
Quality and Efficiency in Health Care (IQWIG) con-
cluded that approvals for orphan drugs, also in rare dis-
eases, are largely based on conventional randomized
designs so that the general feasibility is not in question
[18]. Irrespective of reaching a pre-specified significance
level, randomization leads to the best unbiased estimate
of the treatment effect. Moreover, if the treatment effect
is large, a small RCT will formally prove the effect.
A decision making strategy based on RCTs
A comparison of decision-making strategies based on
single-arm trials versus RCTs is outlined in Fig. 1. Par-
ticularly in those cases, where the natural history of the
disease is not well understood, there is no good reason
to attempt to answer a new research question utilizing a
single-arm trial. Likewise, the risk that patient selection
for a single-arm trial cannot be detected, speaks against
this research approach. Often the discussion is centered
on assessment of efficacy, but also the proper evaluation
of safety is hampered by basing decision making on
single-arm trials. Particularly in situations, where pa-
tients are multi-morbid and treated with many different
drugs, it is difficult to attribute (and balance) effects
without a control arm.
Strikingly and in contrast to the prevailing opinion,
starting with an RCT from the beginning economizes
patients (option 1). In addressing a new research ques-
tion, a small RTC generates valuable data, which serves
as a valid foundation for estimating the treatment effect
unbiasedly and provides good information about the
variability of this treatment effect as a basis for planning
a next adequately powered RCT.
Particularly in the field of rare disease, the decision-
making process may then be based on a meta-analysis of
both RCTs (this approach would be in line with planning
the trial as a two-stage adaptive design according to
Bauer & Köhne [19]) including the first pilot and the
definite trial. Even if the research question is not finally
answered, the data from the two trials can complement
each other and can eventually be combined with a future
RCT. Here, the primary goal of the first RCT is not
proof of efficacy by reaching a pre-specified significance
level (for which the trial cannot be planned for properly
with no prior information on the treatment effect vari-
ability available), but to establish the best possible basis
for continuing research and, eventually, planning a sec-
ond, properly powered RCT. Consequently, in reviewing
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the results of the first RCT most weight should be at-
tached to the evaluation of the treatment effect estimate
instead of focusing on the significance and dismissing
further research, when non-significant results are seen.
This idea is reflected in the two-stage adaptive design by
Bauer & Köhne [19], where interim analysis results will
be available that can be critically challenged, but most
importantly be discussed with a limited competent audi-
ence to decide whether (a) the trial should proceed, (b)
treatment modalities require some modifications to an
extent that allows combining findings of the two stages
or (c) to stop the trial because of “true” futility. Even in
the last case, the trial is informative for future research
in this area because it can provide a control effect
(and its variability) for planning future trial that is relevant
for a randomized situation and free from undetected se-
lection bias towards patients with good prognosis.
When conducting a single-arm trial first (option 2),
the resultant data is frequently less circumspect, treat-
ment effects and effects of patient selection cannot be
separated, which may lead to the conduct of another
single-arm clinical trial and will eventually lead to deci-
sions based on insufficient evidence (2b). In other in-
stances data is regarded as inconclusive and an RCT is
planned based on the single-arm clinical trials (2a). In
addition to all previously mentioned problems of this ap-
proach, more assumptions are needed to include earlier
stages of development with single-arm trials into the
evaluation of this final RCT. In an extreme case, another
RCT based on the first RCT may be necessary and inter-
est may go lost.
Since route 2b does not cumulate appropriate evidence
for decision-making, one can only consider routes 1 and
2a. While both strategies afford interpretable results,
route 2a is less straight forward, a detour of sorts. Only
route 1 accrues meaningful data throughout all clinical
trials and the total sample size is less than compared
with the sample size in route 2a. Only consequently
starting research with RCTs ensures that all treated pa-
tients contribute to the overall evidence and no data is
wasted. As our goal should be to base decision-making
on unbiased estimates of the treatment effect, randomiz-
ing patients is the most economic approach. Following
this strategy, RCTs can be interpreted as Lego®-type
(randomized) building blocks that – similar to the chil-
dren’s toy - can be combined and re-used creatively to craft
stable (evidence) structures. The combination of effect esti-
mates from RCTs in a meta-analysis, or the use as priors in
a Bayesian analysis requires far fewer assumptions than the
combination of results from single-arm trials. In a clinical
decision making context combining RCT results requires
the assumption of equal treatment effects (and not neces-
sarily equal baseline event rates, or an identical structure of
the patient population). In fact, this assumption is always
made, whenever multi-center or multi-regional clinical tri-
als are conducted and stratification for center or region is
considered sufficient to account for potential structural dif-
ferences between centres and regions in the concomitant
setting. In contrast, combining and comparing of single-
arm results is based on the assumption of equal effects,
equal baseline rates, and equal structure in the combined/
compared populations. All these are non-testable or assess-
able from the single arm trial.
By standardizing for baseline rates and the effect of back-
ground treatment in general, the Lego®-type (randomized)
building blocks are combinable more flexibly. In instances,
Fig. 1 Global view of study planning
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a fine-tuning may be needed in between the first and the
second trial, but researchers are used to discuss, under
which circumstances trials can be combined in a meta-
analysis, or not. The randomized building may also be in-
formative, if the intervention is modified to improve safety,
but without any expectation that efficacy is influenced.
When illustrating the global view of study planning, we
focus on single-arm trials as antagonists of RCTs. The
underlying rationale, however, holds true for all study de-
signs as antagonists, which include some sort of control
data without randomizing treatment allocation, as well.
It is disputable, if and how well-planned observational
studies and registries can play a part in our global view
of study planning. We feel that observational research
and particularly the implementation of disease registries,
carefully planned and cautiously interpreted, is a must in
situations, where information is sparse and therefore
highly valuable. The availability of such data would im-
prove the basis for planning of trials, help to assess gen-
eral improvements of patient care and help to better
guess, how many patients can likely be recruited for a
certain clinical trial. In any case, avoidance of selection
bias and representativity of the observed patients need
to be addressed.
Conclusions
While planning an RCT in FA, a rare disease, we en-
countered preferences from numerous stakeholders in
favour of a single-arm trial. This preference was based
on another single-arm trial where improvement of
symptoms was seen that may have implications for the
progression of disease. In the months of planning, it be-
came clear that another randomized trial in the same
condition and investigating the same drug was termi-
nated due to a slow accrual. Although this trial has not
been completed, it became clear, that an improvement
of the symptoms was possible even under placebo and
that the first single-arm trial had hugely overestimated
the treatment effect. The unbiased estimate for the treat-
ment effect would be clinically relevant if measured
against the expected risks of the experimental treatment
and the debilitating consequences of current treatment
options for later stages of disease. In consequence,
current knowledge should actually make the research
approach attractive to confirm short-term- and long-
term effects of treatment. Exaggerated hopes based on
the single-arm trial, however, lead to disappointment
and reservations against the idea to pursue the research
approach. We assume that this is not the first example
for research strategies that have been abandoned irre-
spective of whether there is a more promising or at least
competing approach to be investigated, or not.
Due to these problems, we decided that a cautionary
remark about the place of single-arm trials in today’s
pharmacological decision-making process and research
strategies was important. Moreover, when reading old dis-
cussions about this topic, we felt that particularly in rare
disease there is merit in planning the research strategy
based on RCTs as combinable building blocks that provide
unbiased estimates of the treatment effect and, more im-
portantly, avoid undocumented selection of patients.
Nothing has changed since Chalmers [14], Sibbald &
Roland [5], and Haffner et al. [6]: Single-arm trials are
linked to a wide field of problems, such as debatable
interpretation, lower quality of evidence, unrecognized
predictive or prognostic factors, and overestimation of
the treatment effect derived from a comparison to ef-
fects seen outside the current trial. The conduct of RCTs
suffers from reluctance on both, the researchers’ and the
patients’ side in planning and participating in an RCT if
an apparent effect has been observed in the single arm
trial. Often, however unlikely in rare disease, an RCT is
only conducted after several single-arm trials, if these
lead to obvious heterogeneity and the need of an RCT
becomes inevitable. While on a micro-level it might
seem that single-arm trials are the better choice in dis-
eases with limited patient recruitment, this renders the
accrual-argument of single-arm proponents invalid and
speaks for planning research strategies with randomized
building blocks.
Even though it is clear that research needs to start
somewhere and it is probably not possible to literally fol-
low Chalmers’ advice, particularly in rare disease, the risk
that planning a single-arm trial may generate wasteful
information that is, at best, difficult to be used in future
research should be seen as a disincentive for single-arm
trials. Considering in addition, that most of the efforts to
conduct drug trials lie in the formal need to agree to the
protocol with various stakeholders clarifies that the add-
itional investment of implementing a randomisation and
introducing a control is probably the smallest part in the
discussion.
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